Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder
There are three purposes to this study. The first purpose is to evaluate the value of a genetic test in determining risk for autism spectrum disorder. Processing for genetic samples will be completed at the Cleveland Clinic using research equipment provided by IntegraGen. The second purpose is to identify genetic changes that may be associated with autism spectrum disorder or attention deficit/hyperactivity disorder. The third purpose is to examine whether genetic differences and changes may predict which individuals benefit from medicine used to treat attention problems or other psychiatric difficulties.
Between 600-800 people are expected to participate in this study - approximately 300 individuals with an autism spectrum disorder, 75 individuals with attention deficit/hyperactivity disorder or another developmental or psychiatric disorder, 100 healthy siblings, and 125 unrelated individuals without a developmental or psychiatric disorder.
Study procedures will vary based upon the specific group participants are suspected to fall into (autism, attention deficit/hyperactivity disorder, psychiatric concerns/developmental delay, healthy sibling, or unrelated healthy control).
- All individuals will be asked to participate in a cheek swab (gently swabbing the inside of your cheek) to obtain cells used for genetic testing. Genetic material will be stored with identifiers such as numbers, letters or codes.
- Parents or caregivers will be asked to complete questionnaires that examine medical and family history as well as current symptoms and quality of life for the participant.
- Participants may undergo speech and language testing. This involves answering questions, looking at pictures or identifying items.
- Information recorded in participant medical records will be reviewed and collected for this study.
Autism Spectrum Disorder
Attention Deficit/Hyperactivity Disorder
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Understanding Genetic Differences Associated With Autism Spectrum and Attention Deficit/Hyperactivity Disorder|
- Autism Spectrum Disorder clinical diagnosis [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Genetic material via a cheek swab will be collected.
|Study Start Date:||January 2012|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Participants with autism spectrum disorder.
Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
Siblings without a developmental or psychiatric disorder.
Unrelated individuals without a developmental or psychiatric disorder.
|Contact: Allison Voormanfirstname.lastname@example.org|
|Contact: Becky Embacher, M.Ed.||email@example.com|
|United States, Ohio|
|Cleveland Clinic Center for Autism||Recruiting|
|Cleveland, Ohio, United States, 44104|
|Contact: Allison Voorman 216-448-6421 firstname.lastname@example.org|
|Contact: Becky Embacher, M.Ed. 216.448.6493 email@example.com|
|Principal Investigator: Thomas W Frazier, Ph.D.|
|Principal Investigator: Charis Eng, M.D., Ph.D.|
|Sub-Investigator: Rocio Moran, M.D.|
|Sub-Investigator: Sumit Parikh, M.D.|
|Sub-Investigator: Leslie Speer, Ph.D., NCSP|
|Sub-Investigator: Michael Manos, Ph.D.|
|Sub-Investigator: Elaine Schulte, M.D., MPH|
|Principal Investigator:||Thomas W Frazier, Ph.D.||The Cleveland Clinic|
|Principal Investigator:||Charis Eng, M.D., Ph.D.||The Cleveland Clinic|